Biography

I graduated from Manchester University with a first class honours degree in Pharmacy in 1974, and was awarded a PhD from Manchester University in 1978. 

I have worked as a hospital pharmacist in the NHS for 36 years of which 24 years as a chief pharmacist.  I was Director of Pharmacy at the University Hospital of North Staffordshire and Senior Lecturer at Keele University from 1991-2003, during which time I was also Director of Research and Development for the Hospital.

I moved to become Clinical Director of Pharmacy at Royal Wolverhampton NHS Trust in February 2003.  I was also Professor of Pharmacy at Wolverhampton University from 2004 to 2014, and was instrumental in establishing the undergraduate School of Pharmacy at the University. 

In 2014 I was seconded to the Centre for Medicines optimisation at Keele University as Secondary Care Pharmaceutical advisor and Professor of Clinical Pharmacy, and I continue to work here following my retirement from the NHS in November 2015.

In 2007 I was made a Fellow of the Royal Pharmaceutical Society for distinction in the Profession of Pharmacy and in 2013 I was made a Fellow of the Faculty of the Royal Pharmaceutical Society. I received a lifetime achievement award from the Royal Pharmaceutical Society in 2015 for innovation, leadership and outstanding contribution to pharmacy and a lifetime achievement award from Royal Wolverhampton NHS Trust in 2016.

Research and scholarship

Having spent over two thirds of my career as a Hospital Chief Pharmacist, I have developed a special interest in Medicines Optimisation and Pharmacy practice research, with over 100 publications in journals and book chapters and presentations at national and international conferences.  I have also acted as an advisor to NHS and government bodies on medicines management and prescribing issues.

My current research interests include:

  • The uptake of biosimilars medicines in the NHS.
  • Antibiotics and Clostridium Difficle
  • Hospital Pharmacy workforce issues.

Selected Publications

  • Miljković N, Gibbons N, Batista A, Fitzpatrick RW, Underhill J, Horák P. 2019. Results of EAHP's 2018 Survey on Medicines Shortages. Eur J Hosp Pharm, vol. 26(2), 60-65. link> doi> full text>
  • Aladul MI, Fitzpatrick RW, Chapman SR. 2019. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis. Res Social Adm Pharm, vol. 15(3), 310-317. link> doi> full text>
  • Aladul MI, Fitzpatrick RW, Chapman SR. 2017. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. BioDrugs, vol. 31(6), 533-544. link> doi>
  • Aladul MI, Fitzpatrick RW, Chapman SR. 2017. Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey. BioDrugs, vol. 31(5), 439-446. link> doi> full text>
  • Chapman SR, Fitzpatrick R, Aladul M. 2017. . Patients’ understanding and attitudes towards infliximab and etanercept biosimilars: Result of a UK web-based survey. BioDrugs. doi>

Full Publications List show

Journal Articles

  • Miljković N, Gibbons N, Batista A, Fitzpatrick RW, Underhill J, Horák P. 2019. Results of EAHP's 2018 Survey on Medicines Shortages. Eur J Hosp Pharm, vol. 26(2), 60-65. link> doi> full text>
  • Aladul MI, Fitzpatrick RW, Chapman SR. 2019. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis. Res Social Adm Pharm, vol. 15(3), 310-317. link> doi> full text>
  • Aladul MI, Fitzpatrick RW, Chapman SR. 2017. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. BioDrugs, vol. 31(6), 533-544. link> doi>
  • Aladul MI, Fitzpatrick RW, Chapman SR. 2017. Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey. BioDrugs, vol. 31(5), 439-446. link> doi> full text>
  • Chapman SR, Fitzpatrick R, Aladul M. 2017. . Patients’ understanding and attitudes towards infliximab and etanercept biosimilars: Result of a UK web-based survey. BioDrugs. doi>
  • Chapman SR, Fitzpatrick RW, Aladul MI. 2017. Has cost inhibited the uptake of more potent statins in England?. Pharmacoepidemiol Drug Saf, vol. 26(8), 984-991. link> doi> full text>
  • Ramsbottom H, Rutter P, Fitzpatrick R. 2018. Post discharge medicines use review (dMUR) service for older patients: Cost-savings from community pharmacist interventions. Res Social Adm Pharm, vol. 14(2), 203-206. link> doi> full text>
  • Chapman SR, Fitzpatrick RW, Aladul MI. 2016. Did Cost Inhibit the Uptake of More Potent Statins?. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol. 25, 7. link> doi> full text>
  • Fitzpatrick R and Sanders S. 2016. Hospital pharmacy staffing levels in England: has anything changed in the last 5 years. European Journal of Hospital Pharmacy. doi> link>
  • Ramsbottom HF, Fitzpatrick R, Rutter P. 2016. Post discharge medicines use review service for older patients: recruitment issues in a feasibility study. International journal of clinical pharmacy, vol. 38(2), 208-212. doi> link>
  • Fitzpatrick R. Is Wolverhampton showing the way for pharmacists in GP practices?. Health Services Journal. link>
  • Fitzpatrick R and Pate R. 2015. Assessing the Impact of NICE Guidance on the Prescribing of Hormonal Treatments of Breast Cancer in England. Journal of Evaluation in Clinical Practice, vol. 21, 759-961.
  • Fitzpatrick R, Rutter P, Rutter J. 2015. What Effect does Medicines Advice provided by UK Medicines Information Pharmacists have on Prescriber practice and patient care: a qualitative primary care study. Journal of Evaluation in Clinical Practice,, vol. 21, 307-312. doi> link>
  • Fitzpatrick R, Scott DGI, Keary I. 2013. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate. Clinical Rheumatology, vol. 32, 1605-1612. doi> link>
  • Boardman H and Fitzpatrick R. 2001. Self reported clinical pharmacist interventions under-estimate their input to patient care. Pharm World Sci, vol. 23(2), 55-59. link> doi>
  • Panton R and Fitzpatrick R. 1996. The involvement of pharmacists in professional and clinical audit in the UK: a review and assessment of their potential role. J Eval Clin Pract, vol. 2(3), 193-198. link> doi>

Other

  • Ramsbottom H and Rutter P. 2016. A questionnaire survey of hospital pharmacists’ views on recruiting older patients to a post discharge medicines use review (dMUR) service. International Journal of Pharmacy Practice (vol. 24, p. 39). Pharmaceutical Press.
  • Fitzpatrick R. 2014. Homecare Medicines: Maximising the Benefits and Reducing the Risks. Hospital Pharmacy Europe (vol. 76, p. 11). Campden Publishing.
  • Chapman SR and Fitzpatrick R. Aladul M, Fitzpatrick R, Chapman S. CP-024 Factors affecting uptake of biosimilars Eur J Hosp Pharm 2017;24:A10-A11. Eur J Hosp Pharm 2017;24:A10-A11..
Top 10 CUG Top 5 Guardian Athena SWAN